Puma Biotechnology: Updated Timelines And A Resurgence In Sentiment

Summary

• Puma Biotechnology remains undervalued despite steady neratinib sales and a promising, though early-stage, pipeline.
• Neratinib's combination with trastuzumab deruxtecan shows intriguing signals, especially in pancreatic cancer, but pivotal data won't arrive until 2026.
• Alisertib's phase 2 trials in breast and lung cancer are ongoing, but the lack of recent data keeps its potential speculative for now.
• With positive cash flow, manageable debt, and upcoming catalysts, I reaffirm my cautiously optimistic 'Buy' rating on PBYI.

Daniel Grizelj

Topline Summary and Update

Puma Biotechnology, Inc. (NASDAQ:PBYI) is the ever-tenacious odd duck with an approved drug, reasonably good sales, and a continuing pipeline, but no market appreciation. There are very good reasons for this, but I have remained cautiously optimistic

Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.